期刊文献+

不同剂量瑞舒伐他汀对不稳定斑块中MMP影响 被引量:3

Effects of different dose rosuvastatin on expressions of matrix MMP-2and MMP-9 in unstable plaque in rabbits
原文传递
导出
摘要 目的建立不稳定斑块动物模型,探讨不同剂量瑞舒伐他汀对不稳定斑块中基质金属蛋白酶(MMP)-2、9及血脂影响。方法健康雄性新西兰大白兔40只,随机分为对照组、模型组及低、高剂量瑞舒伐他汀组,每组10只,饲养8周;观察实验前后总胆固醇(TC)、低密度脂蛋白(LDL)、高密度脂蛋白(HDL)、甘油三酯(TG)水平,免疫组化分析不稳定斑块中MMP-2、9表达。结果高、低剂量瑞舒伐他汀组兔血清中TC分别为(11.97±0.35)、(13.73±0.35)mmol/L,TG分别为(6.24±0.37)、(7.53±0.36)mmol/L,LDL分别为(4.28±0.23)、(4.83±0.25)mmol/L,HDL分别为(1.93±0.24)、(1.62±0.22)mmol/L;与模型组比较,高、低剂量瑞舒伐他汀组兔血清TC、TG及LDL的水平均降低(P<0.01),HDL水平均升高(P<0.05);免疫组化结果显示,高、低剂量瑞舒伐他汀组兔腹主动脉不稳定斑块中MMP-2、9表达均较模型组减少(P<0.05)。结论瑞舒伐他汀通过改善血脂水平及抑制MMP-2、9的表达稳定动脉粥样斑块。 Objective To explore effects of rosuvastain on expressions of matrix metalloproteinase-2(MMP-2)and matrix metalloproteinase-9(MMP-9)in vulnerable plaque in rabbits.Methods Fourty healthy male New Zealand white rabbits were randomly divided into four groups:control group(n=10),vulnerable plaque group(n=10),low dose rosuvastatin group(n=10,1 mg/kg/d)and high dose rosuvastatin group(n=10,2 mg/kg/d).Total cholesterol(TC),low-density lipoprotein cholesterol(LDL-C),high-density lipoprotein cholesterol(HDL-C),and triglyceride(TG)were detected before and 1 month after the treatment,respectively.At the end of experiment,all rabbits were sacrificed and expressions of MMP-2 and MMP-9 were determined with immunohistochemical assays.Results Compared to the control group,the concentrations of TC,TG,and LDL-C significantly decreased in rosuvastain treatment groups(11.93&plusmn;0.35 and 13.73&plusmn;0.35 mmol/L,6.24&plusmn;0.37 and 7.53&plusmn;0.36 mmol/L,and 4.28&plusmn;0.23 and 4.83&plusmn;0.25 mmol/L for high dose and low dose group);the concentration of HDL-C increased significantly(1.93&plusmn;0.24 for high dose group and 1.62&plusmn;0.22 mmol/L for low dose group)(P〈0.05 for all).The results of immunohistochemical assays showed that the expressions of MMP-2 and MMP-9 in unstable plague of abdominal aorta were significantly decreased in high and low dose rosuvastatin treatment groups(P〈0.05 for all)compared to that of control group.Conclusion Rosuvastatin improves blood lipid levels and reduces expressions of MMP-2 and MMPv9 which might stabilize the atherosclerotic plaques in rabbits.
出处 《中国公共卫生》 CAS CSCD 北大核心 2013年第10期1482-1484,共3页 Chinese Journal of Public Health
基金 辽宁省自然科学基金(20092106)
关键词 瑞舒伐他汀 动脉粥样硬化 血脂 基质金属蛋白酶(MMP) rosuvastatin atherosclerosis blood lipid MMP-2 MMP-9
  • 相关文献

参考文献11

二级参考文献64

  • 1仲琳,张运,张梅,季哓平,陈文强,姚桂华,丁士芳,张鹏飞.兔动脉粥样硬化易损斑块模型的建立[J].基础医学与临床,2005,25(4):370-374. 被引量:30
  • 2奉水东,凌宏艳,陈新,赵英,龙理良,李凤华.胰岛素抵抗大鼠血和血管壁一氧化氮变化分析[J].中国公共卫生,2006,22(7):797-797. 被引量:4
  • 3田枫,康爱君,张阔,周淑佩,郑振辉.载脂蛋白E基因敲除小鼠血小板与血脂及白细胞总数的关系[J].中国老年学杂志,2006,26(10):1392-1393. 被引量:6
  • 4Kaplan IV, Levinson SS. Apolipoprotein and related testing as markets for coronary artery disease[J].Lab Medica International, 1998, 15(1) :12-14. 被引量:1
  • 5Almagor M, Keren A, Banal S. Increased C-reactive protein level after coronary stent implantation in patients with stable conronary artery disease[J]. Am Heart J, 2003, 145(2) :248 -253. 被引量:1
  • 6Ridker PM, Hennekens CH, Buring JE, et al. C-reactive protein and other markets of inflammation in the prediction of cardiovascular disease in women [ J ]. N Engl J Med, 2000, 342 ( 12 ) :836 - 843. 被引量:1
  • 7Ridker PM, Rifai N, Pfeffer MA, et al. Inflammation ,pravastatin, and the risk of coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events (CARE) Investigators[ J ]. Circulation, 1998, 98 (9) :839 - 844. 被引量:1
  • 8Haverkate F,Thompson SG, Pyke SD, et al. Produclion of C-reactive protein and risk of coronary events in stable and unstable angina. European Concerted Action on Thrombosis and Disabilities Anginal Pectoris Study Group[J]. Lancet, 1997, 349(9050) :462 -466. 被引量:1
  • 9Taniguchi H, Momiyama Y, Ohmori R, et al. Associations of plasma C-reactive protein levels with the presence and extent of coronary stenosis in patients with stable coronary artery disease[J]. Atherosclerosis, 2005, 178 ( 1 ) : 173 - 177. 被引量:1
  • 10Ridker PM, Cannon CP, Morrow D, et al. C-reactive protein levels and outcomes after statin therapy [ J ]. N Engl J Med, 2005, 352 (1) :20 -28. 被引量:1

共引文献43

同被引文献13

引证文献3

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部